208 studies found
pDCs from healthy donors (n=4) were treated with gardiquimod (TLR7 agonist) or ODN 2216 (TLR9 agonist) with or without BTK inhibitor for 3 hours.
Screening of ~5500 FDA-approved drugs and clinical candidates for anti-SARS-CoV-2 activity
Peripheral blood was collected from adults with eosinophilic asthma (EA; n=21), paucigranulocytic asthma (PGA; n=22), neutrophilic asthma (NA; n=9), and healthy controls (n =10). Blood monocytes were isolated using ficoll density gradient and immuno-magnetic cell separation. Bisulfite converted genomic DNA was hybridised to Illumina Infinium Methylation27 arrays, and analysed for differential methylation using R/Bioconductor packages
Refer to individual Series
In total 153 arrays were analyzed with 6 technical replicates (147 biological samples). CD34+ stem cells, CD4+ T-cells, resting CD14+ monocytes, stimulated monocytes and macrophages were analyzed, all from patient with severe coronary atherosclerosis or controls that had no coronary atherosclerosis as determined angiographically, and which were carefully matched for age and gender.
Biopsies from one of four anatomic locations, from healthy controls and treated (with non-biologic standard of care) or untreated CD patients.
Peripheral blood samples were obtained at week 0 and week 4 of tocilizumab treatment and global gene expression profiling identified markers of responder status.